Pfizer Inc. (NYSE:PFE) Shares Sold by Hendershot Investments Inc.

Hendershot Investments Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 2.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,449 shares of the biopharmaceutical company’s stock after selling 1,150 shares during the quarter. Hendershot Investments Inc.’s holdings in Pfizer were worth $1,165,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Worth Asset Management LLC purchased a new stake in Pfizer in the 1st quarter worth about $29,000. Briaud Financial Planning Inc acquired a new position in shares of Pfizer in the 3rd quarter valued at about $30,000. GoalVest Advisory LLC lifted its position in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer during the third quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC boosted its holdings in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PFE. Truist Financial cut their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 1st. Barclays reduced their price target on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a report on Thursday, December 14th. UBS Group dropped their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. Finally, Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Stock Performance

Shares of PFE traded down $0.48 on Wednesday, reaching $26.31. 44,507,787 shares of the stock traded hands, compared to its average volume of 42,980,691. The stock’s 50-day moving average price is $27.33 and its 200-day moving average price is $29.02. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm has a market cap of $148.95 billion, a price-to-earnings ratio of 73.22, a P/E/G ratio of 1.19 and a beta of 0.61. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $41.99.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the prior year, the company posted $1.14 EPS. The business’s revenue was down 41.3% on a year-over-year basis. Equities analysts forecast that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.